Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 757 of the 757 references it cites were found in a registry or an index.

Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines

Open access
Cleare, Anthony, Pariante, CM, Young, AH, Anderson, IM, Christmas, D, Cowen, PJ, Dickens, C, Ferrier, IN, Geddes, J, Gilbody, S, Haddad, PM, Katona, C, Lewis, G, Malizia, A, McAllister-Williams, RH, Ramchandani, P, Scott, J, Taylor, D, Uher, R, the members of the Consensus Meeting · 2015 · Journal of Psychopharmacology

Abstract

A revision of the 2008 British Association for Psychopharmacology evidence-based guidelines for treating depressive disorders with antidepressants was undertaken in order to incorporate new evidence and to update the recommendations where appropriate. A consensus meeting involving experts in depressive disorders and their management was held in September 2012. Key areas in treating depression were reviewed and the strength of evidence and clinical implications were considered. The guidelines were then revised after extensive feedback from participants and interested parties. A literature review is provided which identifies the quality of evidence upon which the recommendations are made. These guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing and management, next-step treatment, relapse prevention, treatment of relapse and stopping treatment. Significant changes since the last guidelines were published in 2008 include the availability of new antidepressant treatment options, improved evidence supporting certain augmentation strategies (drug and non-drug), management of potential long-term side effects, updated guidance for prescribing in elderly and adolescent populations and updated guidance for optimal prescribing. Suggestions for future research priorities are also made.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0269881115581093

Cites

757 of 757 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

8 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 750 references

Research works printed but not linked: 61

  1. Al-Jumah KA, 2012, Patient Prefer Adherence, 6, 87
  2. 10.1177/026988110001400101 · DOI · Paper page
  3. Anderson L, 2005, Brit J Gen Pract, 55, 387
  4. Angst J, 1993, Clin Neuropharmacol, 16, S55
  5. Ballenger JC, 2001, J Clin Psychiatry, 62, 47
  6. Barrett JE, 2001, J Fam Pract, 50, 405
  7. Bedson E, 2014, Health Technol Assess, 18, vii
  8. Brunoni AR, 2009, Ther Clin Risk Manage, 5, 897
  9. 10.1002/1520-6394(2001)13:1<38::AID-DA6>3.0.CO;2-7 · DOI
  10. Chew-Graham A, 2007, Br J General Pract, 57, 364
  11. Clayton AH, 2003, Int Clin Psychopharmacol, 18, 151
  12. Cohen J, 1988, Statistical Power Analysis for the Behavioral Sciences, 2nd edn
  13. Danish University Antidepressant Group, 1986, Psychopharmacol (Berl), 90, 131
  14. Davidson JRT, 1999, J Clin Psychiatry, 4
  15. Delgado PL, 2004, J Clin Psychiatry, 65, 16
  16. Dornseif BE, 1989, Psychopharmacol Bull, 25, 71
  17. Dubini A, 1997, J Psychopharmacol, 11, S17
  18. Ekers D, 2007, Psychol Med, 1
  19. Fava M, 1995, J Clin Psychiatry, 56, 52
  20. 10.1034/j.1600-0447.2001.00148.x · DOI
  21. Furukawa TA, 2002, Cochrane Database Syst Rev, 1
  22. 10.1053/smrv.2002.0235 · doi:10.1053/smrv.2002.0235 · Paper page
  23. Goldberg D, 1998, Br J Gen Pract, 48, 1840
  24. Greden JF, 1993, J Clin Psychiatry, 54, 39
  25. Hannaford PC, 1996, Br J Gen Pract, 46, 333
  26. Hardy M, Coulter I, Morton C, et al. (2001) Agency for Healthcare Research and Quality (US Department of Health and Human Services); S-Adenosyl-L-Methionine for Treatment of Depression, Osteoarthritis, and Liver Disease. Evidence Reports/Technology Assessments, No. 64. Available at: http://www.ncbi.nlm.nih.gov/books/NBK36942/ (accessed 10 February 2015).
  27. Healy D, 1997, J Psychopharmacol, 11, S25
  28. Heun R, 2012, CINP Vancouver 2012
  29. Hoffman L, 2003, Am J Manag Care, 9, 70
  30. Joint Formulary Committee, 2014, British National Formulary
  31. 10.1046/j.1440-1614.2002.01026.x · doi:10.1046/j.1440-1614.2002.01026.x
  32. Katon W, 1997, J Clin Psychiatry, 58, 20
  33. Kennedy SH, 2006, J Psychiatry Neurosci, 31, 122
  34. Khan A, 1991, Neuropsychopharmacology, 4, 125
  35. Lader M, 1983, J Clin Psychiatry, 44, 20
  36. Montejo AL, 2001, J Clin Psychiatry, 62, 10
  37. Morgan O, 2004, Health Stat Q, 23, 18
  38. Nihalani ND, 2007, Curr Opin Investig Drugs, 8, 563
  39. Ottevanger EA, 1991, Br J Clin Res, 2, 125
  40. Piet J, 2011, CliniPsychol Rev, 31, 1032
  41. Reimherr FW, 2001, J Clin Psychiatry, 16
  42. Revicki DA, 1998, J Fam Pract, 47, 446
  43. Richards A, 2003, Br J Gen Pract, 53, 764
  44. Robinson DS, 1991, Psychopharmacol Bull, 27, 31
  45. Robinson P, 1997, J Fam Pract, 44, 562
  46. Rouillon F, 1991, J Clin Psychiatry, 52, 423
  47. Royal College of Psychiatrists, 2000, Council Report CR89
  48. 10.1016/j.biopsych.2005.05.025 · DOI · Paper page
  49. 10.1037/0022-006X.67.6.837 · DOI · Paper page
  50. Shepherd DJ, 2009, The Psychiatrist, 33, 41
  51. 10.1002/(SICI)1099-1077(199709/10)12:5<509::AID-HUP915>3.0.CO;2-1 · doi:10.1002/(sici)1099-1077(199709/10)12:5<509::aid-hup915>3.0.co;2-1
  52. Thase ME, 1997, J Clin Psychiatry, 158, 23
  53. 10.1177/0269881107081550 · doi:10.1177/0269881107081550 · Paper page
  54. Trivedi M, 2012, J Assoc Physicians India, 60, 28
  55. Tylee A, 1995, Br J Gen Pract, 45, 575
  56. Waite J, 2013, The ECT Handbook
  57. Walters G, 1999, J Clin Psychiatry, 60, 21
  58. Watson S, 2014, J Psychopharmacol, 28, A38
  59. Wilkinson MJ, 1988, J R Coll Gen Pract, 38, 311
  60. Wise T, 2014, Neuropsychiatr Dis Treat, 10, 1
  61. World Health Organization, 1992, The ICD-10 Classification of Mental and Behavioural Disorders - Clinical Descriptions and Diagnostic Guidelines

Cited by

See all 759

Metadata

Authors
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., Haddad, P., Katona, C., Lewis, G., Malizia, A., McAllister-Williams, R., Ramchandani, P., Scott, J., Taylor, D., Uher, R., & Meeting, T. M. O. T. C.
Affiliations
  • King's College London (GB)
  • Professor of Biological Psychiatry, King’s College London, Institute of Psychiatry, Psychology and Neuroscience, Centre for Affective Disorders, London, UK
  • Professor of Psychiatry and Chair of Mood Disorders, King’s College London, Institute of Psychiatry, Psychology and Neuroscience, Centre for Affective Disorders, London, UK
  • Professor and Honorary Consultant Psychiatrist, University of Manchester Department of Psychiatry, University of Manchester, Manchester, UK
  • Ninewells Hospital (GB)
  • Professor of Psychopharmacology, Psychopharmacology Research Unit, Neurosciences Building, University Department of Psychiatry, Warneford Hospital, Oxford, UK
  • University of Exeter (GB)
  • Professor of Psychiatry, Honorary Consultant Psychiatrist, School of Neurology, Neurobiology & Psychiatry, Royal Victoria Infirmary, Newcastle upon Tyne, UK
  • Warneford Hospital (GB)
  • University of York (GB)
  • Consultant Psychiatrist, Cromwell House, Greater Manchester West Mental Health NHS Foundation Trust, Salford, UK
  • University College London (GB)
  • North Bristol NHS Trust (GB)
  • Reader in Clinical Psychopharmacology, Institute of Neuroscience, Newcastle University, Royal Victoria Infirmary, Newcastle upon Tyne, UK
  • Centre for Mental Health (GB)
  • Newcastle University (GB)
  • Dalhousie University (CA)
Venue
Journal of Psychopharmacology
Published
2015-05
Volume
29
Issue
5
Pages
459-525
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W2155959499
Cited by
759
References
750
Citations by year
2026: 39 · 2025: 73 · 2024: 71 · 2023: 54 · 2022: 92 · 2021: 110 · 2020: 71 · 2019: 76 · 2018: 60 · 2017: 48 · 2016: 47 · 2015: 12
FWCI
40.11
Type
journal article
Language
en
Open access
Licence
  • other-oa
  • journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (publishedVersion, other-oa)
  • UCL Discovery (University College London) (submittedVersion)
  • Research Explorer (The University of Manchester) (submittedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Funders
Medical Research Council
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
depressive disorders, antidepressants, depression treatment, evidence-based clinical guidelines, relapse prevention, relapse treatment, treatment discontinuation, augmentation strategies, antidepressant side effects, adolescent depression
MeSH terms
Antidepressive Agents, Combined Modality Therapy, Depressive Disorder, Humans, Evidence-Based Medicine, Consensus, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. https://app.cochat.ai/papers/10.1177/0269881115581093
The paper
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., Haddad, P., Katona, C., Lewis, G., Malizia, A., McAllister-Williams, R., Ramchandani, P., Scott, J., Taylor, D., Uher, R., & Meeting, T. M. O. T. C. (2015). Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology. https://doi.org/10.1177/0269881115581093

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.